Table 2

Univariate analyses of clinicopathological variables affecting clinical outcomes

	Disease-free survival			Overall survival
Variables	HR	95% CI	p Value	HR	95% CI	p Value
Age: <50 vs ≥50 years	1.192	0.833 to 1705	0.336	0.897	0.604 to 1.330	0.588
Histological grade: 3 vs 1/2	0.796	0.547 to 1.158	0.232	0.789	0.517 to 1.205	0.273
pT	1.909	1.425 to 2.557	<0.001	1.707	1.223 to 2.385	0.002
Lymphovascular invasion: positive vs negative	3.078	2.181 to 4.345	<0.001	2.838	1.919 to 4.197	<0.001
Lymph node metastasis: positive vs negative	2.505	1.772 to 3.540	<0.001	2.251	1.523 to 3.329	<0.001
pTNM stage	2.118	1.639 to 2.737	<0.001	1.972	1.476 to 2.635	<0.001
Percentage of in situ component	0.996	0.983 to 1.009	0.523	0.993	0.978 to 1.008	0.364
Basal type: positive vs negative	1.153	0.802 to 1.658	0.443	0.992	0.663 to 1.484	0.97
Radiation therapy: negative vs positive	1.277	0.863 to 1.888	0.221	1.272	0.818 to 1.978	0.285
Chemotherapy: AC vs ACT	0.645	0.543 to 0.767	<0.001	0.684	0.563 to 0.832	<0.001
TILs (per 10%)	0.982	0.976 to 0.989	<0.001	0.981	0.973 to 0.989	<0.001
Germinal centres in the interior of the invasive area: positive vs negative	0.362	0.148 to 0.885	0.026	0.39	0.143 to 1.060	0.065
Peritumoral lymphocytic infiltration	0.64	0.516 to 0.793	<0.001	0.582	0.456 to 0.743	<0.001
TLSs in adjacent tissue	0.681	0.573 to 0.810	<0.001	0.642	0.529 to 0.779	<0.001
Germinal centres in adjacent tissue: positive vs negative	0.517	0.360 to 0.741	<0.001	0.443	0.291 to 0.674	<0.001
Percentage of tumour stroma: high vs low	1.136	0.874 to 1.476	0.339	0.989	0.757 to 1.291	0.993
Invasive tumour composition: homogeneous vs heterogeneous	0.87	0.600 to 1.260	0.461	0.936	0.613 to 1.430	0.76

AC, anthracycline and cyclophosphamide; ACT, anthracycline, cyclophosphamide and taxane; pT, pTNM, pathological tumour, nodes and metastasis; TIL, tumour-infiltrating lymphocyte; TLSs, tertiary lymphoid structures.